プレスリリース

Illumina to Webcast Live Presentations at Upcoming Events in January

SAN DIEGO--(BUSINESS WIRE)--Dec. 23, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Company’s presentations at two upcoming events.

Illumina will webcast its presentation at the JP Morgan 32nd Annual Healthcare Conference in San Francisco, California on January 14, 2014. The live webcast is scheduled to begin at 8:30 AM PT and will feature a presentation by Jay Flatley, Chief Executive Officer.

The company will also host an Investor Day in San Francisco on January 16, 2014 beginning at 1:00 PM PT, which will be webcast live. This event will feature an update on the company’s businesses and markets. Attendance at this event is by invitation.

The webcast can be accessed in the Investor Relations section of Illumina's web site under the "Company" tab at www.illumina.com.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Recent Articles

英国がゲノム研究とより良いヘルスケアの新しい基準をどのように設定しているか
英国がゲノム研究とより良いヘルスケアの新しい基準をどのように設定しているか
Shriners Children’s big bet on the future of specialized pediatric care
Shriners Children’s big bet on the future of specialized pediatric care
Illumina highlights the importance of HRD testing at ESMO 2023
Video: Illumina highlights the importance of HRD testing at ESMO 2023